The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1
Open accessAbstract
Cardiovascular (CV) disease is the leading cause of morbidity and mortality in both sexes in developed countries, but gender differences exists in its diagnosis and treatment. Gender differences in absorption and distribution and excretion of drugs responsible for gender differences in pharmacokinetic and pharmacodynamic actions. Since the number of women included in CV studies has often been low, most recommendations in women have often been inferred from effects observed in men.1 This position paper discusses the gaps in knowledge on the effects of gender on pharmacokinetics (PK) and pharmacodynamics (PD) of CV drugs. Gender-related differences in PK may arise from differences in body composition, plasma protein binding, metabolizing enzymes and transporters, excretion activity, and/or physiological hormonal changes (Figure 1).2,3 Oral drug absorption is influenced by gastric acid secretion and emptying time, gastrointestinal blood flow and surface area, gut and hepatic metabolism.2,3 Although gender differences in these mechanisms exist, they do not significantly affect drug absorption between the two sexes.2,3 Drug distribution depends on body composition, plasma volume, blood flow, and tissue and plasma protein binding. Women have higher per cent of body fat and lower body weight, plasma volume, and organ blood flow. Increased body fat content explains the faster onset and prolonged duration of action and higher volume of distribution (Vd) of lipophilic drugs, while the Vd of hydrophilic drugs is smaller, producing higher initial plasma levels and greater effects when compared with males.3–5 Plasma and tissue drug concentrations depend on the Vd and clearance (Cl). Exogenous sex hormones increase serum-binding globulins levels.2–5 This effect may be relevant for drugs like warfarin whose 97% is bound to plasma proteins. Hepatic drug Cl is a function of cardiac output and liver blood flow, which are lower in women, while hepatic enzyme activity involved in phase I and II reactions, and transporters exhibit sex-specific differences.3–5 Gender differences in renal excretion for most drugs are attributable to body weight and differences disappear after normalisation for body weight. Despite the effects of oestrogens on PK/PD have been better elucidated than those of testosterone, the influence of sex hormone levels and PK/PD of CV drugs has not been well studied. Phase I studies are often conducted in young healthy volunteers that differ in their hormonal profile to the population of patients that will receive CV treatments. Gender differences in PD are difficult to quantify as women are often under-represented in trials and the role of sex hormones in the final response is not taken into consideration. Unfortunately, the appropriate dosage and the gender differences in clinical outcomes are still not recognized for many drugs routinely used in clinical practice. Aspirin has been suggested to be more active in male than in female platelets, although studies have shown that women have a similar decrease in platelet reactivity after low dose aspirin therapy than men. The benefits of aspirin in secondary prevention are well documented in both sexes.6 Although the effect of aspirin in primary prevention is more controversial, an analysis of primary prevention studies found that aspirin lowered the risk of stroke but not of myocardial infarction (MI) or CV death in females whereas in men aspirin reduced the risk of MI but not the risk of stroke.6,7 No gender difference in the risk of bleeding has been reported. The effects of digoxin on CV mortality and morbidity seem to be sex-dimorphic. In the DIG study, digoxin therapy was associated with an increased risk of death for any cause and with a less-evident reduction in the rate of hospitalization for worsening heart failure in women with heart failure than in men.8 The increased risk of death among women was possibly related to the relatively excessive dosage of digoxin. Although the increased mortality was correlated to the higher serum digoxin concentrations,8 sex-based differences in digoxin PK were absent when actual or ideal body weight was used. Although it is known that plasma levels of beta-blockers do not always correlate with therapeutic efficacy, women present higher plasma level of metoprolol and propranolol due to a slower Cl and lower Vd, which results in a greater reduction in exercise heart rate and systolic blood pressure than men. However, metoprolol might exert a greater therapeutic effect on stress-induced angina pectoris in men than in women in spite of higher plasma levels in females.9 Drug exposure to metoprolol is further increased under therapy with oral contraceptives. Despite some trials suggested that beta-blockers improved survival only in males, but not in females, with hypertension or heart failure several a meta-analysis confirmed that beta-blockers produced a similar survival benefit in heart failure or after MI in both sexes.10
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Sex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163
Cited by
Sex differences in heart failure
Lam, C. S. P., Arnott, C., Beale, A. L., Chandramouli, C., Hilfiker-Kleiner, D., Kaye, D. M., Ky, B., Santema, B. T., Sliwa, K., & Voors, A. A. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz835 · Cited by 802
Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs
Scott, P. E., Unger, E. F., Jenkins, M. R., Southworth, M. R., McDowell, T.-Y., Geller, R. J., Elahi, M., Temple, R. J., & Woodcock, J. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.070 · Cited by 366
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Self-citationHypertension Across a Woman’s Life Cycle
Wenger, N. K., Arnold, A., Bairey Merz, C. N., Cooper-DeHoff, R. M., Ferdinand, K. C., Fleg, J. L., Gulati, M., Isiadinso, I., Itchhaporia, D., Light-McGroary, K., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.033 · Cited by 298
Santema, B. T., Ouwerkerk, W., Tromp, J., Sama, I. E., Ravera, A., Regitz-Zagrosek, V., Hillege, H., Samani, N. J., Zannad, F., Dickstein, K., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31792-1 · Cited by 258
Metadata
- Authors
- Rosano, G. M. C., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., Drexel, H., Patak, A., Torp-Pedersen, C., Kjeldsen, K. P., & Tamargo, J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-05-06
- Volume
- 36
- Issue
- 40
- Pages
- 2677-2680
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W1938468405
- Cited by
- 175
- References
- 3
- FWCI
- 11.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1. https://app.cochat.ai/papers/10.1093/eurheartj/ehv161
- The paper
- Rosano, G. M. C., Lewis, B., Agewall, S., Wassmann, S., Vitale, C., Schmidt, H., Drexel, H., Patak, A., Torp-Pedersen, C., Kjeldsen, K. P., & Tamargo, J. (2015). Gender differences in the effect of cardiovascular drugs: a position document of the Working Group on Pharmacology and Drug Therapy of the ESC: Figure 1. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.